摘要
目的:观察伊曲康唑治疗血液系统恶性肿瘤继发侵袭性真菌感染的临床疗效和安全性。方法:回顾分析了我院血液科2003年7月至2007年7月恶性血液肿瘤继发侵袭性真菌感染患者66例,经伊曲康唑治疗的疗效及安全性。结果:①总有效率为59.1%,其中痊愈6.1%,显效53.0%。确诊病例、临床诊断病例和拟诊病例的有效率分别为75.0%,67.7%和31.2%。检测到真菌组和未检测出真菌组患者抗真菌治疗有效率分别为72.2%(26/36)和43.3%(13/30)。②药物的不良反应总发生率为15.2%。③具有肺部影像学主要特征、次要特征患者的有效率分别为85.3%(29/36)和52.9%(9/17)。④氟康唑或大扶康治疗无效的33例再次应用伊曲康唑后有效19例(57.6%)。结论:伊曲康唑治疗血液系统恶性肿瘤继发侵袭性真菌感染疗效确切,安全可靠,起效较快。但在使用过程中需监测肝肾功能及血电解质。
Objective： To investigate the efficacy and safety of itraconazole on invasive fungal infections in patients with malignant hematological diseases. Methods： Sixty-six patients with malignant hematological diseases, who were diagnosed as invasive fungal infection, were retrospectively analyzed. The patients were treated with itraconazole as long as diagnosed. Results： （1）The total effective rate was 59.1% , including 6.1% of cure rate and 53.0% of significantly improved-rate. The effective rates were 75.0% , 67.7% and 31.2% in the patients with confirmed diagnosis, clinical diagnosis and recommended diagnosis, respectively. The rates were 72. 2% and 43.3% in the patients with and without detected fungi, respectively. （2）The side-effect rate was 15.2% . （3） The effective rate was better in the patients with major imaging signs than in those with secondary imaging signs. （4）Of 33 patients who failed to the therapy of fluconazole, 19 patients were still sensitive to itroconazole. Conclusion： Itraconazole is effective and safe in the treatment of invasive fungal infections in patients with hematological malignancy. However, the hepatic and renal functions should be tested regularly during the use of itraconazole.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2009年第4期323-326,共4页
Chinese Journal of New Drugs
关键词
伊曲康唑
血液肿瘤
侵袭性真菌感染
itraconazole
neoplastic hematologic disorder
invasive fungal infection
